Amgen Inc.
AMGN
Xếp hạng trong cổ phiếu
#73
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Giá cổ phiếu
$432.49
Đồng bộ lần cuối: 2026-10-16
Vốn hóa thị trường
$233.82B
Thay đổi (1 ngày)
-0.35%
Thay đổi (1 năm)
44.74%
Quốc gia
US
Giao dịch Amgen Inc. (AMGN)
Danh mục
Healthcare
EPS của Amgen Inc. (AMGN)
EPS tính đến June 2026 TTM: $16.22
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Amgen Inc., EPS hiện tại của công ty (TTM) là $16.22. Vào cuối năm 2024, công ty có EPS là $7.62, tăng so với EPS năm 2023 là $12.56.
Lịch sử EPS của Amgen Inc. từ 2000 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| 2026 (TTM) | $16.22 | 13.19% |
| 2025 | $14.33 | 88.06% |
| 2024 | $7.62 | -39.33% |
| 2023 | $12.56 | 3.12% |
| 2022 | $12.18 | 17.79% |
| 2021 | $10.34 | -16.61% |
| 2020 | $12.40 | -4.32% |
| 2019 | $12.96 | 2.05% |
| 2018 | $12.70 | 368.63% |
| 2017 | $2.71 | -73.74% |
| 2016 | $10.32 | 12.79% |
| 2015 | $9.15 | 34.56% |
| 2014 | $6.80 | 0.74% |
| 2013 | $6.75 | 20.32% |
| 2012 | $5.61 | 37.84% |
| 2011 | $4.07 | -15.56% |
| 2010 | $4.82 | 6.40% |
| 2009 | $4.53 | 19.53% |
| 2008 | $3.79 | 33.92% |
| 2007 | $2.83 | 12.75% |
| 2006 | $2.51 | -15.49% |
| 2005 | $2.97 | 59.68% |
| 2004 | $1.86 | 6.29% |
| 2003 | $1.75 | -244.63% |
| 2002 | $-1.21 | -213.08% |
| 2001 | $1.07 | -3.60% |
| 2000 | $1.11 | 0.00% |
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| $29.89 | 84.28% |
US
|
|
| $6.60 | -59.31% |
US
|
|
| $3.55 | -78.11% |
US
|
|
| $1.26 | -92.23% |
US
|
|
| $20.39 | 25.70% |
CH
|
